Skip to main content
CF PharmTech, Inc. logo

CF PharmTech, Inc. — Investor Relations & Filings

Ticker · 2652 HKEX Manufacturing
Open in API
Filings indexed 95 across all filing types
Latest filing 2026-05-26 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 2652

About CF PharmTech, Inc.

https://www.cfpharmtech.com

CF PharmTech, Inc. is a commercial-stage specialty pharmaceutical company specializing in the research, development, manufacturing, and commercialization of complex drug delivery systems, primarily focusing on inhalation technologies. The company develops treatments for major respiratory conditions, including asthma, Chronic Obstructive Pulmonary Disease (COPD), and allergic rhinitis. Its core product platforms encompass Inhalation Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), inhalation liquid preparations (nebulizers), and nasal sprays. The firm also leverages advanced formulation techniques, such as liposomes, to enhance drug efficacy and delivery.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 90% confidence The document is an FF305 “Next Day Disclosure Return” filed pursuant to Hong Kong Listing Rules. It details the repurchase of the company’s own shares held as treasury shares and changes in issued share capital. This is a direct report of transactions in the issuer’s own shares (repurchase/sale). Therefore, it falls under Transaction in Own Shares (POS).
2026-05-26 English
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION FOR TIOTROPIUM BROMIDE INHALATION POWDER BY THE NMPA
Regulatory Filings Classification · 75% confidence The document is a voluntary corporate announcement by CF PharmTech regarding the acceptance of its marketing authorization application by the NMPA. It is neither a financial report nor a shareholder meeting document, nor does it relate to governance changes or capital markets. This type of regulatory update falls under general regulatory announcements, making Regulatory Filings (RNS) the appropriate category.
2026-05-26 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 90% confidence The document is a Form FF305 Next Day Disclosure Return under the HKEx Main Board/GEM Rules reporting detailed changes in issued shares and treasury shares, including a share repurchase on-market. It provides tables of share movements, repurchase prices, and confirmations. This matches the definition of a ‘Transaction in Own Shares’ (company buying back or selling its own shares).
2026-05-22 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 90% confidence The document is a Hong Kong Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares and treasury shares, specifically share repurchases and treasury holdings for CF PharmTech, Inc. This is a regulatory announcement of an on‐market share buyback – a report of the company buying back its own shares. Under the classification schema, this falls squarely under “Transaction in Own Shares” (Code: POS).
2026-05-21 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 93% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares, treasury shares and share repurchases by CF PharmTech, Inc. It reports the company’s own share buyback and treasury share transactions. This matches the definition of “Transaction in Own Shares” rather than a general report announcement or dividend notice. Therefore the appropriate category is POS (Transaction in Own Shares).
2026-05-20 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases, including dates, prices, and quantities. The document includes confirmations about compliance with listing rules and legal requirements. It is a regulatory disclosure about share repurchase activity rather than a financial report, earnings release, or management discussion. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length and detail confirm it is not a brief announcement but a formal disclosure report on share transactions by the company itself.
2026-05-19 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.